News

InnoCore Pharmaceuticals appoints new CEO

Groningen, The Netherlands, September 27, 2011

InnoCore Pharmaceuticals, a leading provider of bioresorbable polymer-based drug delivery solutions to the pharmaceutical industry, is pleased to announce the appointment of Jan Hendriks as Chief Executive Officer. He will take over this position from co-founder Theo Flipsen who will continue his involvement in InnoCore Pharmaceuticals as President of the company.

Jan Hendriks (1962) brings over 20 years of experience in the pharmaceutical arena to InnoCore. After having served in clinical research and commercial management positions at Sanofi-Aventis and AstraZeneca, he became CEO of Pharma Bio-Research, a CRO focusing on early clinical research that was sold to PRA in 2005. In that year, he founded HendRx Health, through which he has contributed to the development of several medical and (bio)pharmaceutical organizations. Jan Hendriks obtained his Masters in Pharmaceutical Technology and Pharm.D. degrees at Groningen University and was trained in Business Administration at the same university and at IMD and INSEAD.

"We are delighted to have Jan on board" says Theo Flipsen. "Jan has the right skills and experience to guide InnoCore Pharmaceuticals to its next stage, where we want to further develop and commercialize our polymeric drug delivery technologies and pharmaceutical development capabilities." Jan Hendriks adds: "I'm impressed by what has been accomplished by InnoCore since its foundation in 2003 with respect to the development of bioresorbable polymeric drug eluting coatings for cardiovascular stents and, more recently, with providing drug delivery solutions for parenteral controlled release formulations. It is a real pleasure to experience the enthusiasm and dedication of the scientists and engineers currently employed by InnoCore and I'm looking forward to working with them and to broaden the awareness of our technologies and capabilities in the market".

About InnoCore Pharmaceuticals

InnoCore is a privately owned Dutch biopharmaceutical drug delivery company specialized in the development of novel injectable pharmaceutical drug delivery products and drug eluting medical implants based on its proprietary SynBiosys® biodegradable polymeric drug delivery technology. InnoCore focuses on the development of long-acting and minimally invasive controlled release formulations for precise delivery of small lipophilic molecules, therapeutic peptides and proteins. Its technology portfolio comprises various product configurations, including microspheres, long-acting solid implants, in situ forming gels and coatings. Since its inception in 2003, Innocore has successfully established partnerships with biomedical, biotech and pharma companies throughout the world. Various injectable depot formulations including long-acting solid injectable implants for LHRH-agonist and microsphere formulations for several therapeutic proteins are currently under development. Sirolimus-eluting coronary stents comprising SynBiosys coatings are currently evaluated in Orbusneich' REMEDEE trial. To support its customers during clinical product development InnoCore, in collaboration with its strategic partners, is working on the realization of cGMP facilities for small scale clinical production of SynBiosys microspheres and implants.

To learn more about InnoCore Pharmaceuticals, please visit us at www.innocorepharma.com or contact us at +31 (0)505370819